About GIOSTAR
GIOSTAR is a Healthcare company based in San Diego (United States) founded in 2012. Stem cell therapies for degenerative and genetic diseases are developed. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of stem cell-based therapy for degenerative and genetic diseases. It has developed a technique for the extraction of stem cells from a human body and uses them for autologous and allogeneic stem cells transplant. It claims that it has the ability to treat several immunological diseases and blood-related diseases that include diabetes type I and type II, lupus, multiple sclerosis, Crohns disease, vasculitis, scleroderma, myasthenia gravis, sickle cell anemia, leukemia, lymphoma, thalassemia, and developing the therapies for Alzheimers, Autism, Anti-Aging Treatments, Parkinsons disease, Cancer, Heart and Retinal Degeneration and Spinal Muscular Atrophy (SMA).
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website giostar.com
- Social X Facebook YouTube
- Latest Funding Round$100K (USD), Grant
Apr 2013
- Investors
Associated legal entities of GIOSTAR
GIOSTAR is associated with 3 registered companies on The Company Check. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cancend Research Private Limited CIN U73200GJ2020PTC118883 | Active | 16 Dec 2020 | Ahmedabad, Gujarat | 3 | View details | ||
| Giostar Regen Private Limited CIN U73100GJ2020PTC118853 | Active | 15 Dec 2020 | Ahmedabad, Gujarat | ₹1.6 Cr | 4 | View details | |
| Giostar Research Private Limited CIN U73100GJ2009PTC058156 | Active | 22 Sep 2009 | Ahmedabad, Gujarat | ₹1.9 Cr | 5 | View details |
Apps and channels of GIOSTAR
its YouTube channel GIOSTAR Stem Cell Therapy has 4.38K subscribers.
Funding Insights of GIOSTAR
- Total Rounds 1
- Last Round Grant — $100,000
- First Round $100,000
(Apr 2013)
- Investors Count 1
All 1 funding rounds of GIOSTAR with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $100,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in GIOSTAR
GIOSTAR has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Grand Challenges Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology and business sectors are developed through government-backed initiatives. | 2010 | grandchallenges.ca | Toronto, Canada |
Investor details for GIOSTAR
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of GIOSTAR
The boards of the 3 registered companies of GIOSTAR currently have 5 directors; the longest-serving is Deven Jitendra Patel, appointed in 2009. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Deven Jitendra Patel DIN 02777751 | Director | 22 Sep 2009 | 17 yrs 1 mo | Giostar Research Private Limited, Giostar Regen Private Limited, Cancend Research Private Limited |
| Anand Srivastava Shanker DIN 02778181 | Director | 24 Sep 2009 | 17 yrs 1 mo | Giostar Research Private Limited, Giostar Regen Private Limited, Cancend Research Private Limited |
| Siddharth Bhavsar DIN 06994681 | Director | 15 Mar 2015 | 11 yrs 7 mo | Giostar Research Private Limited |
| Suresh Deopura DIN 08971604 | Director | 26 Jul 2022 | 4 yrs 3 mo | Giostar Research Private Limited, Giostar Regen Private Limited |
| Seetharaman Rajasekar DIN 10794881 | Director | 01 Oct 2024 | 2 yrs | Giostar Research Private Limited, Giostar Regen Private Limited, Cancend Research Private Limited |
Financials of GIOSTAR
Figures of Giostar Research Private Limited, the primary company behind GIOSTAR, for FY 2023. Revenue was ₹1.90 Cr (+13% year on year). Net profit was ₹5.7 Lakh (3% margin). EBITDA was ₹15.5 Lakh (8% margin). Revenue has grown at a compounded annual rate of -18% over three years and -10% over five years.
- ₹1.90 CrRevenue · FY 2023 · +13% YoY
- ₹5.7 LakhNet profit · 3% margin
- ₹15.5 LakhEBITDA · 8% margin
- ₹1 LakhPaid-up capital
- -18%Revenue CAGR, 3 years
- -10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Giostar Research Private Limited are on its company page.
Detailed financial statements for GIOSTAR
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GIOSTAR
2 dated milestones of GIOSTAR across 1 years, from founding to its latest funding, stage changes and deals.
- Founded GIOSTAR is founded.
- Funding First funding round of $100K.
Competitors of GIOSTAR
GIOSTAR has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of GIOSTAR
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GIOSTAR
The website of GIOSTAR (giostar.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 15.8% vs previous month
Websites whose visitors overlap most with GIOSTAR. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stemcellcareindia.com | 100% | 12K | #2,061,646 | View details | |
| globalstemcellcare.com | 35% | 1.1K | #10,728,559 | View details | |
| eyestemcellcenter.com | 26% | #8,766,908 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GIOSTAR (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Giostar
Complete news archive for GIOSTAR
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GIOSTAR
GIOSTAR was founded in 2012 and raised its 1st funding round 1 year after it was founded.
GIOSTAR is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Developer of stem cell-based therapy for degenerative and genetic diseases. It has developed a technique for the extraction of stem cells from a human body and uses them for autologous and allogeneic stem cells transplant. It claims that it has the ability to treat several immunological diseases and blood-related diseases that include diabetes type I and type II, lupus, multiple sclerosis, Crohns disease, vasculitis, scleroderma, myasthenia gravis, sickle cell anemia, leukemia, lymphoma, thalassemia, and developing the therapies for Alzheimers, Autism, Anti-Aging Treatments, Parkinsons disease, Cancer, Heart and Retinal Degeneration and Spinal Muscular Atrophy (SMA).
GIOSTAR's top competitors include BridgeBio, Forge Biologics and Insitro.
GIOSTAR has 1 investor. Key investors include Grand Challenges Canada.
GIOSTAR is associated with 3 legal entities: Giostar Research Private Limited, Giostar Regen Private Limited, Cancend Research Private Limited.
The legal entities of GIOSTAR currently have 5 directors, including Siddharth Bhavsar, Suresh Deopura, Seetharaman Rajasekar and others.